Indivior PLC stock (US45580R1068): Analyst EPS estimates rise ahead of earnings

Analyst estimates for Indivior PLC's 2026 earnings per share have climbed from $3.03 to $3.35 over the past 60 days, signaling optimism as the next earnings release approaches on May 14, 2026.

Indivior PLC, a leader in addiction treatment medications, has seen upward revisions in analyst forecasts for its 2026 earnings. Over the past 60 days, consensus EPS estimates increased from $3.03 to $3.35, according to Zacks as of May 2026. This comes ahead of the company's next earnings report scheduled for May 14, 2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Indivior PLC
• Sector/industry: Pharmaceuticals
• Headquarters/country: United Kingdom
• Core markets: United States, global
• Key revenue drivers: Addiction treatment drugs like SUBLOXONE
• Home exchange/listing venue: Nasdaq (INDV)
• Trading currency: USD

Indivior PLC: core business model

Indivior PLC develops and markets therapies focused on addiction and related serious medical conditions. The company specializes in treatments for opioid use disorder, with its flagship product SUBLOXONE film generating the majority of revenue. Indivior operates primarily in the US market, which accounts for the bulk of its sales, making it highly relevant for US investors tracking pharmaceutical exposure to behavioral health.

Founded as a spin-off from Reckitt Benckiser in 2014, Indivior has built a portfolio around innovative delivery systems for buprenorphine, a key medication in opioid addiction treatment. The RECELL system is not associated with this company; Indivior's focus remains on spray-dried buprenorphine and other pipeline candidates for opioid dependence and schizophrenia.

Main revenue and product drivers for Indivior PLC

SUBLOXONE, a buprenorphine-naloxone film, drives over 80% of Indivior's revenue as of the latest reported periods. The product benefits from strong demand in the US amid the ongoing opioid crisis. PERSERIS, an injectable for schizophrenia, contributes growing sales, with Q4 2025 figures showing sequential improvement per company filings.

Pipeline advancements include OPNT003, a novel buprenorphine formulation targeting faster onset for overdose reversal. US market dynamics, including regulatory support for addiction treatments, bolster Indivior's position for American investors seeking exposure to healthcare innovation.

Why Indivior PLC matters for US investors

Listed on Nasdaq under ticker INDV, Indivior derives most revenue from the United States, directly tying its performance to US healthcare spending and opioid crisis initiatives. Recent corporate actions, such as CUSIP changes noted on Robinhood as of May 2026, reflect ongoing optimization for US trading.

Industry trends and competitive position

The addiction treatment sector benefits from rising US government funding and awareness of substance use disorders. Indivior competes with generic buprenorphine providers but maintains premium positioning through patented formulations. Market data indicates sustained demand, with US prescriptions for opioid treatments up in recent years.

Conclusion

Indivior PLC continues to navigate a critical role in addiction treatment with upward EPS revisions signaling analyst confidence ahead of May 14 earnings. US-centric revenue provides direct exposure to American healthcare trends. Investors monitor upcoming results for confirmation of growth trajectories in key products like SUBLOXONE and PERSERIS.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.